Lifileucel: FDA-approved T-cell therapy for melanoma

This commentary reports on the history of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy and where TIL fits into the treatment options for metastatic melanoma.

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2024-08, Vol.29 (8), p.648-650
Main Authors: Kwong, Mei Li M, Yang, James C
Format: Article
Language:English
Subjects:
Cancer
Care and treatment
Drug therapy
Health aspects
Humans
Immunotherapy, Adoptive - methods
Lymphocytes, Tumor-Infiltrating
Melanoma
Melanoma - drug therapy
Melanoma - immunology
Melanoma - pathology
Melanoma - therapy
Physiological aspects
T cells
T-Lymphocytes - immunology
United States
United States Food and Drug Administration
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This commentary reports on the history of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy and where TIL fits into the treatment options for metastatic melanoma.
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1093/oncolo/oyae136